Levacetylleucine

Brand names: Aqneursa · Active ingredient: Levacetylleucine

In short: AQNEURSA® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. AQNEURSA is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.

Forms & strengthsFor oral suspension: 1 gram levacetylleucine as white to off-white strawberry flavored granules in a unit-dose packet.
LabelIntraBio Inc
Label updatedNov 16, 2026

What is Levacetylleucine used for?

AQNEURSA® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.

AQNEURSA is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.

Levacetylleucine dosage

For females of reproductive potential, verify that the patient is not pregnant .

The recommended dosage of AQNEURSA to be administered orally, with or without food, is based on the patient’s actual body weight (kg), as shown in

Table 1

.

For AQNEURSA doses of 2 grams, prepare two packets individually .

Patient’s Body Weight | Morning Dose | Afternoon Dose | Evening Dose

15 kg to less than 25 kg | 1 gram | No Dose | 1 gram

25 kg to less than 35 kg | 1 gram | 1 gram | 1 gram

35 kg or more | 2 grams | 1 gram | 1 gram

One AQNEURSA packet contains 1 gram levacetylleucine.

Missed Dose

If a dose of AQNEURSA is missed, skip the missed dose and take the next dose at the scheduled time. Do not take 2 doses at the same time to make up for a missed dose.

Oral Administration

For oral administration, administer AQNEURSA as follows:

1. Obtain the required number of AQNEURSA packets for the prescribed dose (one or two packets).

2. Open and empty the entire contents of one AQNEURSA packet into a container with 40 mL of water, orange juice, almond milk, or yogurt. Do not use hot liquid.

3. Stir to form a suspension.

4. Swallow the suspension immediately (within 30 minutes).

5. For doses requiring two AQNEURSA packets, repeat steps 2 to 4.

6. Discard unused AQNEURSA suspension if not administered within 30 minutes.

Use of Gastrostomy Tube (G-Tube) for Feeding Tube Administration

For patients who have a G-tube (French size 12 or larger) in place, administer AQNEURSA as follows:

1. Prepare AQNEURSA suspension immediately before administration via gastrostomy tube.

2. Obtain the required number of AQNEURSA packets for the prescribed dose (one or two packets).

3. Open and empty the entire contents of one AQNEURSA packet into a container with 40 mL of water ONLY. Do not use hot liquid.

4. Stir to form a suspension.

5. Draw up the suspension into a catheter tip syringe.

6. Administer the suspension immediately through the G-tube.

7. Flush any residual suspension in the catheter tip syringe with an additional 20 mL of water.

8. Flush the G-tube again, as needed, until no residual suspension is left in the syringe or feeding tube.

9. For doses requiring two AQNEURSA packets, repeat steps 3 to 8.

10. Discard unused AQNEURSA suspension if not administered immediately.

How to take Levacetylleucine — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Instructions for Use).

Embryo-Fetal Toxicity

AQNEURSA may cause embryo-fetal harm. Advise a pregnant female of the potential risk to the fetus. Advise a female of reproductive potential and caregiver to inform their healthcare provider of a known or suspected pregnancy . Advise a female of reproductive potential to use effective contraception during treatment and for 7 days after the last dose if AQNEURSA is discontinued .

Distributed by: IntraBio Inc., Austin TX 78701

AQNEURSA® is a registered trademark of IntraBio.

© 2026 IntraBio, Inc. All rights reserved.

Warnings & precautions

Do not take this medicine if: None.

Based on findings from animal reproduction studies, AQNEURSA may cause embryo-fetal harm when administered during pregnancy. Administration of levacetylleucine to pregnant rats and rabbits during the period of organogenesis caused an increase in embryo-fetal death (post implantation loss/resorption) and skeletal malformations at a dose that was approximately 1.4-fold and 6-fold, respectively, the maximum recommended human dose (MRHD) of 4 g/day of levacetylleucine (based on body surface area).

The decision to continue or discontinue AQNEURSA treatment during pregnancy should consider the female’s need for AQNEURSA, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease.

For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with AQNEURSA. Advise females of reproductive potential to use effective contraception during treatment with AQNEURSA and for 7 days after the last dose if AQNEURSA is discontinued .

Levacetylleucine side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Niemann-Pick Disease Type C

The safety of AQNEURSA was evaluated in Trial 1, which included a total of 60 patients with Niemann-Pick disease Type C (NPC), in a placebo-controlled, randomized, crossover trial . The mean (SD) treatment duration of AQNEURSA was 86.2 (4.7) days (69 min, 97 max); the mean (SD) treatment duration on placebo was 87.3 (4.8) days (78 min, 113 max).

Table 2 summarizes adverse reactions that occurred in patients who were treated with AQNEURSA in Treatment Period I of Trial 1.

Adverse Reaction | AQNEURSA

N=30

n (%) | Placebo

N=30

n (%)

Upper respiratory tract infection | 5 (17) | 1 (3)

Abdominal pain | 2 (7) | 0 (0)

Dysphagia | 2 (7) | 0 (0)

Vomiting | 2 (7) | 0 (0)

Rosacea

One patient experienced an exacerbation of rosacea during Trial 1 that responded to treatment. AQNEURSA was not discontinued.

Laboratory Findings

Thrombocytopenia with platelets < 100 10^3 cells/µL was observed in four patients during Treatment Period 1 of Trial 1, all of whom were receiving miglustat for 42 days or longer at the time of enrollment. In two of these patients, the thrombocytopenia was present at baseline. In the other two patients, the thrombocytopenia developed during Trial 1. …

Drug interactions

N-acetyl-DL-leucine and N-acetyl-D-leucine

Avoid concomitant use of AQNEURSA with N-acetyl-DL-leucine and N-acetyl-D-leucine. The D-enantiomer, N-acetyl-D-leucine, competes with levacetylleucine for monocarboxylate transporter uptake, which may reduce the levacetylleucine efficacy.

P-glycoprotein (P-gp) Transporter Substrates

Monitor more frequently for P-gp substrate related adverse reactions when used concomitantly with AQNEURSA.

Levacetylleucine inhibits P-gp . However, the clinical significance of this finding has not been fully characterized.

About this medicine

AQNEURSA (levacetylleucine) for oral suspension contains the drug substance levacetylleucine, a modified amino acid. Levacetylleucine is slightly soluble in aqueous solutions. The chemical name is 2-acetamido-4-methylpentanoic acid. The empirical formula is C8H15NO3 and the molecular weight is 173.21. The chemical structure is:

Each packet of AQNEURSA granules contains 1 gram levacetylleucine and the inactive ingredients hypromellose, isomalt and strawberry flavor.

How it works: The distinct molecular target for levacetylleucine in the treatment of NPC or A-T is unknown. Clinical pharmacodynamic studies have not been conducted for levacetylleucine. A relationship was not observed between increasing levacetylleucine exposure and clinical efficacy.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0f248e55-d1bb-13f9-e063-6294a90a05ce. Read the full official label on DailyMed.